CMPS vs CNSP

COMPASS Pathways Plc - American vs CNS Pharmaceuticals, Inc. — Valuation Comparison 2026

CMPS

Pharmaceutical Preparations
COMPASS Pathways Plc - American
Quality
1.9
out of 10
Value Trap
12
SAFE
Price
$13.06
Last close
Models
9/13
Active
VS

CNSP

Pharmaceutical Preparations
CNS Pharmaceuticals, Inc.
Quality
3.6
out of 10
Value Trap
39
LOW
Price
$5.44
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType CMPS Fair ValueCMPS Upside CNSP Fair ValueCNSP Upside
Bayesian DCF Intrinsic $2.95 -77.4% $2.43 -55.3%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.47 -95.5% $1.10 -52.2%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $14.06 +24.7%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CMPS vs CNSP — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CMPS vs CNSP — Which Stock Is More Undervalued?

CNSP scores higher with a 3.6/10 quality rating vs CMPS's 1.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing COMPASS Pathways Plc - American (CMPS) and CNS Pharmaceuticals, Inc. (CNSP) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CMPS currently trades at $13.06 with a QOC of 1.9/10, while CNSP trades at $5.44 with a QOC of 3.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).